Page 115 - Read Online

Hochhalter et al. Association between HCMV and GBM

Exp Neurol 2014;73:994-8. malignant transformation of tumor cells. Small GTPases
55. Libard S, Popova SN, Amini RM, Kärjä V, Pietiläinen T, Hämäläinen 2014;5:e29019.
KM, Sundström C, Hesselager G, Bergqvist M, Ekman S, Zetterling 72. Mazieres J, Antonia T, Daste G, Muro-Cacho C, Berchery D, Tillement
M, Smits A, Nilsson P, Pfeifer S, de Ståhl TD, Enblad G, Ponten V, Pradines A, Sebti S, Favre G. Loss of RhoB expression in human
F, Alafuzoff I. Human cytomegalovirus tegument protein pp65 is lung cancer progression. Clin Cancer Res 2004;10:2742-50.
detected in all intra- and extra-axial brain tumours independent of the 73. Ferguson SD, Srinivasan VM, Ghali MG, Heimberger AB.
tumour type or grade. PLoS One 2014;9:e108861. Cytomegalovirus-targeted immunotherapy and glioblastoma: hype or
56. Ahani N, Nikravesh A, Shirkoohi R, Karimi Arzenani M, Rokouei M, hope? Immunotherapy 2016;8:413-23.
Eskandani MA. Detection of human cytomegalovirus in glioma tumor 74. Schaller TH, Sampson JH. Advances and challenges: dendritic
tissues. Comparative Clin Pathol 2014;23:1321-30. cell vaccination strategies for glioblastoma. Expert Rev Vaccines
57. Tang KW, Hellstrand K, Larsson E. Absence of cytomegalovirus in 2017;16:27-36.
high-coverage DNA sequencing of human glioblastoma multiforme. 75. Nair SK, De Leon G, Boczkowski D, Schmittling R, Xie W, Staats J,
Int J Cancer 2015;136:977-81. Liu R, Johnson LA, Weinhold K, Archer GE, Sampson JH, Mitchell
58. Wakefield A, Pignata A, Ghazi A, Ashoori A, Hegde M, Landi D, Gray DA. Recognition and killing of autologous, primary glioblastoma
T, Scheurer ME, Chintagumpala M, Adesina A, Gottschalk S, Hicks tumor cells by human cytomegalovirus pp65-specific cytotoxic T
J, Powell SZ, Ahmed N. Is CMV a target in pediatric glioblastoma? cells. Clin Cancer Res 2014;20:2684-94.
Expression of CMV proteins, pp65 and IE1-72 and CMV nucleic 76. University PS. A Phase I-II Study of Allogeneic CMV Specific
acids in a cohort of pediatric glioblastoma patients. J Neurooncol Cytotoxic T Lymphocytes (CTL) for Patients With Refractory
2015;125:307-15. Glioblastoma Multiforme (GBM). In: ClinicalTrials.gov [Internet].
59. Bianchi E, Roncarati P, Hougrand O, Guérin-El Khourouj V, Boreux Bethesda (MD): National Library of Medicine (US); 2000. Available
R, Kroonen J, Martin D, Robe P, Rogister B, Delvenne P, Deprez M. from: http://clinicaltrials.gov/show/NCT00990496 NLM Identifier:
Human cytomegalovirus and primary intracranial tumors: frequency NCT00990496. [Last accessed on 2017 Feb 22]
of tumor infection and lack of correlation with systemic immune anti- 77. Medicine BCo. Phase I/II Administration of CMV (Cytomegalovirus)-
viral responses. Neuropathol Appl Neurobiol 2015;41:e29-40. Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme
60. Shamran HA, Kadhim HS, Hussain AR, Kareem A, Taub DD, Price (COGLI). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National
RL, Nagarkatti M, Nagarkatti PS, Singh UP. Detection of human Library of Medicine (US); 2000. Available from: http://clinicaltrials.
cytomegalovirus in different histopathological types of glioma in Iraqi gov/show/NCT01205334 NLM Identifier: NCT01205334. [Last
patients. Biomed Res Int 2015;2015:642652. accessed on 2017 Feb 22]
61. Lin CT, Leibovitch EC, Almira-Suarez MI, Jacobson S. Human 78. Florida Uo. Peptide Targets for Glioblastoma Against Novel
herpesvirus multiplex ddPCR detection in brain tissue from low- Cytomegalovirus Antigens. In: ClinicalTrials.gov [Internet]. Bethesda
and high-grade astrocytoma cases and controls. Infect Agent Cancer (MD): National Library of Medicine (US); 2000. Available from:
2016;11:32. http://clinicaltrials.gov/show/NCT01854099 NLM Identifier:
62. Taha MS, Abdalhamid BA, El-Badawy SA, Sorour YM, Almsned NCT01854099. [Last accessed on 2017 Feb 22]
FM, Al-Abbadi MA. Expression of cytomegalovirus in glioblastoma 79. Center MDAC. A Phase I/II Clinical Trial of Autologous
multiforme: myth or reality? Br J Neurosurg 2016;30:307-12. Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Glioblastoma
63. Stangherlin LM, Castro FL, Medeiros RS, Guerra JM, Kimura LM, (GBM) Patients. In: ClinicalTrials.gov [Internet]. Bethesda
Shirata NK, Nonogaki S, Dos Santos CJ, Carlan Silva MC. Human (MD): National Library of Medicine (US); 2000. Available from:
cytomegalovirus DNA quantification and gene expression in gliomas http://clinicaltrials.gov/show/NCT02661282 NLM Identifier:
of different grades. PLoS One 2016;11:e0159604. NCT02661282. [Last accessed on 2017 Feb 22]
64. Soderberg-Naucler C, Rahbar A, Stragliotto G. Survival in 80. Florida Uo. A Phase II Randomized, Blinded, and Placebo-controlled
patients with glioblastoma receiving valganciclovir. N Engl J Med Trial of CMV RNA-Pulsed Dendritic Cells With Tetanus-Diphtheria
2013;369:985-6. Toxoid Vaccine in Patients With Newly-Diagnosed Glioblastoma. In:
65. Stragliotto G, Rahbar A, Solberg NW, Lilja A, Taher C, Orrego A, ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of
Bjurman B, Tammik C, Skarman P, Peredo I, Söderberg-Nauclér Medicine (US); 2000. Available from: http://clinicaltrials.gov/show/
C. Effects of valganciclovir as an add-on therapy in patients with NCT02465268 NLM Identifier: NCT02465268. [Last accessed on
cytomegalovirus-positive glioblastoma: a randomized, double-blind, 2017 Feb 22]
hypothesis-generating study. Int J Cancer 2013;133:1204-13. 81. Gary Archer DUMC. Peptide Targets for Glioblastoma Against
66. Cobbs CS. Does valganciclovir have a role in glioblastoma therapy? Novel Cytomegalovirus Antigens. In: ClinicalTrials.gov [Internet].
Neuro Oncol 2014;16:330-1. Bethesda (MD): National Library of Medicine (US); 2000. Available
67. Peng C, Wang J, Tanksley JP, Mobley BC, Ayers GD, Moots PL, Clark from: http://clinicaltrials.gov/show/NCT02864368 NLM Identifier:
SW. Valganciclovir and bevacizumab for recurrent glioblastoma: a NCT02864368. [Last accessed on 2017 Feb 22]
single-institution experience. Mol Clin Oncol 2016;4:154-8. 82. Gary Archer DUMC. Evaluation of Overcoming Limited Migration
68. Söderberg-Nauclér C, Johnsen JI. Cytomegalovirus in human brain and Enhancing Cytomegalovirus-specific Dendritic Cell Vaccines
tumors: role in pathogenesis and potential treatment options. World J With Adjuvant TEtanus Pre-conditioning in Patients With Newly-
Exp Med 2015;5:1-10. diagnosed Glioblastoma. In: ClinicalTrials.gov [Internet]. Bethesda
69. Tseliou M, Al-Qahtani A, Alarifi S, Alkahtani SH, Stournaras C, (MD): National Library of Medicine (US); 2000. Available from:
Sourvinos G. The role of RhoA, RhoB and RhoC GTPases in cell http://clinicaltrials.gov/show/NCT02366728 NLM Identifier:
morphology, proliferation and migration in human cytomegalovirus NCT02366728. [Last accessed on 2017 Feb 22]
(HCMV) infected glioblastoma cells. Cell Physiol Biochem 83. Gary Archer DUMC. AVeRT: Anti-PD-1 Monoclonal Antibody
2016;38:94-109. (Nivolumab) in Combination With DC Vaccines for the Treatment of
70. Porter AP, Papaioannou A, Malliri A. Deregulation of Rho GTPases in Recurrent Grade III and Grade IV Brain Tumors. In: ClinicalTrials.
cancer. Small GTPases 2016;7:123-38. gov [Internet]. Bethesda (MD): National Library of Medicine (US);
71. Orgaz JL, Herraiz C, Sanz-Moreno V. Rho GTPases modulate 2000. Available from: http://clinicaltrials.gov/show/NCT02529072
Neuroimmunology and Neuroinflammation ¦ Volume 4 ¦ June 16, 2017 107